Advanced Prostate Cancer: Treatment Advances and Future Directions

Umang Swami; Taylor R McFarland; Roberto Nussenzveig; Neeraj Agarwal

doi:10.1016/j.trecan.2020.04.010

Advanced Prostate Cancer: Treatment Advances and Future Directions

Trends Cancer. 2020 Aug;6(8):702-715. doi: 10.1016/j.trecan.2020.04.010. Epub 2020 Jun 10.

Authors

Umang Swami¹, Taylor R McFarland¹, Roberto Nussenzveig¹, Neeraj Agarwal²

Affiliations

¹ Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.

PMID: 32534790
DOI: 10.1016/j.trecan.2020.04.010

Abstract

Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Appropriate drug selection remains crucial in this evolving landscape to derive maximum benefit for the patients. We summarize clinical trials leading to recent drug approvals and discuss optimal treatment selection. We also review recent advances in genomics including its evolving role in prognosis, in elucidating mechanisms of treatment resistance, and in guiding treatment decisions.

Keywords: abiraterone; apalutamide; cabazitaxel; darolutamide; docetaxel; enzalutamide; metastatic prostate cancer.

Publication types

Review

MeSH terms

Androgen Antagonists / pharmacology
Androgen Antagonists / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics
Bone Neoplasms / blood
Bone Neoplasms / diagnosis
Bone Neoplasms / secondary
Bone Neoplasms / therapy*
Clinical Decision-Making
Clinical Trials as Topic
Humans
Liquid Biopsy / methods
Male
Neoplasm Staging
Patient Selection
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Positron Emission Tomography Computed Tomography / methods
Prostate / diagnostic imaging
Prostate / drug effects
Prostate / pathology*
Prostate / radiation effects
Prostatic Neoplasms / blood
Prostatic Neoplasms / diagnosis
Prostatic Neoplasms / genetics
Prostatic Neoplasms / therapy*
Radiopharmaceuticals / pharmacology
Radiopharmaceuticals / therapeutic use
Theranostic Nanomedicine
Treatment Outcome

Substances

Androgen Antagonists
Biomarkers, Tumor
Poly(ADP-ribose) Polymerase Inhibitors
Radiopharmaceuticals